<code id='7BA0898A66'></code><style id='7BA0898A66'></style>
    • <acronym id='7BA0898A66'></acronym>
      <center id='7BA0898A66'><center id='7BA0898A66'><tfoot id='7BA0898A66'></tfoot></center><abbr id='7BA0898A66'><dir id='7BA0898A66'><tfoot id='7BA0898A66'></tfoot><noframes id='7BA0898A66'>

    • <optgroup id='7BA0898A66'><strike id='7BA0898A66'><sup id='7BA0898A66'></sup></strike><code id='7BA0898A66'></code></optgroup>
        1. <b id='7BA0898A66'><label id='7BA0898A66'><select id='7BA0898A66'><dt id='7BA0898A66'><span id='7BA0898A66'></span></dt></select></label></b><u id='7BA0898A66'></u>
          <i id='7BA0898A66'><strike id='7BA0898A66'><tt id='7BA0898A66'><pre id='7BA0898A66'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:44665
          Illustration of a hospital being handed from a doctor to a business person – politics and policy coverage from STAT
          New guidelines from federal antitrust enforcers would have big implications on health care deals. Adobe

          Health care companies trying to merge can expect tougher policing from the top federal antitrust agencies, according to a set of new draft guidelines released Wednesday.

          The Department of Justice and Federal Trade Commission laid out 13 proposed guidelines detailing how they will judge whether proposed mergers and acquisitions are anticompetitive and should be challenged.

          advertisement

          The rules would apply broadly across the economy, but they have strong implications for the health care industry, where sizable deals among hospitals, physician practices, private equity firms, health insurers, pharmacy benefit managers, pharmaceutical companies, medical device firms, and numerous other entities occur almost weekly. Research has shown that health care’s highly concentrated markets are a major reason why prices and spending have soared for patients and taxpayers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Readout Newsletter: The latest from Bristol, Sarepta, and Novartis
          Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

          CourtesyBristolMyersSquibbWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetour

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Dark money group runs ads on China biotech bill

          BGIGrouphasbeentargetedbyadarkmoneygroupsupportingtheBIOSECUREAct.STR/AFPviaGettyImagesYou’rereading